Q4 2025 Earnings Call March 5, 2026 4:30 PM ESTCompany ParticipantsAllan Kells - Vice President of Investor RelationsSean Duffy ...
A new study finds that popular GLP-1 drugs used to treat diabetes and obesity show new promise in fighting multiple substance use disorders.
GoodRx reports that GLP-1 medications will expand in use and accessibility, with new oral options and evolving insurance coverage trends.
The "nanoparticle" system sends genetic instructions via mRNA directly to the cells that produce insulin, blocking the body's immune system attack on insulin-producing beta cells in the pancreas.
Doctors warn that AI isn't perfect, but the info will likely be more personalized and specific than what patients might find through a Google search.
In the current landscape of accelerating digital global trade, mobile devices are becoming a vital gateway for international procurement. An increasing number of overseas buyers are completing ...
GLP-1s were first approved in 2005 for the treatment of Type 2 diabetes. Since then, more versions of the medication have hit the market, becoming more accessible to patients and used for a wider ...
Florida, United States, February 28, 2026 -- At the height of the global GLP-1 drug surge, five-time international bestselling author Jay Campbell has released his most disruptive and timely work to ...
Explore the benefits of the Precision GLP-1 agonist, a new therapy that improves glycaemic control and reduces side effects.
MindRank, a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced that the first ...
Bilingual telehealth provider MiSalud Health today announced a $25/month all-inclusive GLP-1 support program. Its goal is to ...
The Allspring Premier Large Company Growth Fund lagged its benchmark in Q4 2025 despite gains from Natera. Read the full analysis for more details.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results